Oxford BioMedica PLC (OXBDF) (H1 2026) Earnings Call Highlights: Revenue Climbs 10% as Client ...

• Warning! GuruFocus has detected 5 Warning Signs with OXBDF.

• Is OXBDF fairly valued? Test your thesis with our free DCF calculator.

Release Date: September 22, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript .

Positive Points

• Oxford BioMedica PLC ( OXBDF ) signed 17 new clients in H1 2026, more than 30% of the total signed in full year 2025, with the number increasing to 22 by the time of the call, demonstrating strong commercial momentum.

• The commercial pipeline grew to $713 million at the half year, up from $659 million at the end of August 2025, and contracted orders increased from GBP97 million to GBP127 million by end of August, improving revenue visibility.

• Oxford BioMedica PLC ( OXBDF ) has 59 active client programs as of September 2026, up from 44 a year earlier, with 29 new programs onboarded and a 34% increase in total programs, including a significant rise in AAV projects.

• The company expects multiple late-stage programs to reach BLA submission within the next 12 months, which should drive future commercial manufacturing revenue and deepen client relationships.

• Oxford BioMedica PLC ( OXBDF ) reported H1 2026 revenue of GBP80.2 million, a 10% increase year-over-year on a constant currency basis, driven by a 20% increase in manufacturing revenues.

• Operating EBITDA improved by GBP0.5 million to a loss of GBP7.8 million, and adjusted EBITDA improved by GBP1.4 million to a loss of GBP2.5 million, reflecting cost discipline and operating leverage.

• The company maintains its full-year 2026 revenue guidance of GBP180-200 million, with GBP168 million already covered by contracted orders, and reaffirms its 2027 targets of 25-30% revenue growth and double-digit EBITDA margins.

• Oxford BioMedica PLC ( OXBDF ) is well-positioned in the growing cell and gene therapy market, with a global footprint across the UK, US, and France, and a diversified client base that mitigates concentration risk.

Negative Points

• Oxford BioMedica PLC ( OXBDF ) reported an operating EBITDA loss of GBP7.8 million in H1 2026, although this was an improvement from the prior year, the company remains unprofitable at the operating level.

• The company recognized a GBP7.6 million impairment of property, plant and equipment related to its France site due to lowered near-term revenue expectations, indicating challenges in that region.

• Oxford BioMedica PLC ( OXBDF ) experienced a net cash outflow of GBP34.3 million from December 2025 to June 2026, ending with cash of GBP75.3 million, partly due to working capital timing and lower accruals.

• Client programs were deferred or delayed due to changes in client strategy or clinical data, and some clients adopted a more staged approach to ordering work packages, extending the time to realize full contract value.

• Durham operations faced a delay of around six months on GMP operational readiness, which impacted timelines, though the first GMP run has now been completed.

• The company's August guidance update was driven by timing-related factors, and the full-year 2026 revenue guidance was maintained but not increased, suggesting limited upside to near-term expectations.

• Licenses and royalties revenue decreased to GBP1.2 million as Kymriah matures, reflecting declining revenue from older products.

• Oxford BioMedica PLC ( OXBDF ) faces inherent risks in the CDMO business, including clinical trial failures, regulatory delays, and funding constraints for clients, which can lead to program cancellations and revenue volatility.

Q & A Highlights

Q: Miles Dixon of Peel Hunt asked whether the timing issues flagged in the August trading update have started to unwind since then, given Durham is now online and a new program was announced today, and separately asked whether any of the GBP200 million commercial revenue underpinning the FY2030 GBP500 million target came from autoimmune programs. A: CFO Lucinda Crabtree confirmed the answer is yes with Durham online and the service offering in place, pipeline is converting into contracted orders that will pivot to revenue, and she expects that momentum to gather. Chief Commercial Officer Sebastien Ribault added that the only autoimmune programs in the GBP500 million projections are Cabaletta and Kyverna, both of which have disclosed excellent clinical data (Cabaletta in June, Kyverna around late March/early April) and have treated over 100 patients, with active discussions ongoing on patient numbers and batch requirements.

Q: Zain Ebrahim of JPMorgan asked why 2026 revenue coverage rose only about GBP3 million even though roughly GBP30 million of orders were added since August, and whether the change in customer ordering behavior is a one-off tied to specific customers or clinical failures. A: CFO Lucinda Crabtree said the GBP168 million coverage figure is being managed against a high-conviction pipeline, with focus on shorter-lead-time development activity. Chief Commercial Officer Sebastien Ribault stressed the numbers on the slides are a snapshot and contracts are signed "every day," with coverage already higher. He said the staged ordering behavior is not one-off but a structural funding-driven shift: European clients facing constrained access to capital now sign feasibility, process development and GMP work as separate contracts rather than one end-to-end deal, adding roughly 8 to 10 weeks of cumulative delay per program. He cited the Alliance for Regenerative Medicine Q2 2026 snapshot showing $9.4 billion of global CGT investment in H1 2026, of which Europe accounted for only $0.7 billion.

Q: Christopher Richardson of Jefferies asked how much of the shortfall against the 2023-2026 medium-term revenue growth target is due to recent unforeseen program delays versus assumptions made three years ago that proved too ambitious around market demand, client conversion or manufacturing ramp. A: Chief Commercial Officer Sebastien Ribault said market dynamics have not changed assets grew between September 2025 and September 2026 and late-stage/pre-registration programs rose 18% year on year. The shortfall came from a very limited number of programs: with only about 50 active programs, issues on three (a cancellation, a clinical issue, and a regulatory timeline delay) have an outsized impact. He noted roughly nine in ten programs will still fail clinically, so pipeline growth must continue, and that dependence on client forecasts and regulatory agency timing means bumps are inherent to the CDMO business.

Q: James Orsborne of Stifel asked how client attrition this year compares with prior years and peers, and how hiring and facilities should be viewed given late-stage programs and BLAs expected within 12 months. A: Chief Commercial Officer Sebastien Ribault said conversion rates are stable at plus or minus 1% versus the Capital Markets Day, and technical attrition of 80% to 95% simply reflects the market, clinical data and funding environment he sees no meaningful difference versus 2025 and does not expect 2027 to differ. On capacity, he said OXB's capacity plan and go-to-market strategy are aligned and no network capacity expansion is expected before 2029 at the earliest, while the company actively pursues post-Phase II programs given its existing commercial track record in both the UK and US.

Q: James Orsborne of Stifel asked whether there is a margin difference between the AAV and lentiviral product lines, and whether AAV growth outpacing lentivirus changes site management. A: Chief Commercial Officer Sebastien Ribault said his expectations for AAV are the same as for lentivirus, with no reason to discount OXB's technical experience. He highlighted high-quality final product, high productivity, excellent yields and a strong safety profile from the amount of fully capped species delivered to clients, which he attributed to the company's innovation investments the same logic applied to lentivirus.

Q: Julie Simmonds of Panmure Liberum asked how large the cancellation revenues booked in 2025 were, to better gauge underlying growth, and about the CapEx spend weighting between this year and next. A: CFO Lucinda Crabtree said the cancellation revenue was a reasonable amount, around the low single-digit range, without giving specifics. On CapEx, she noted spend was relatively modest in H1 and is expected to ramp, but remains well within the roughly GBP50 million aggregate guidance for 2026 and 2027, with some weighting toward 2027 versus 2026.

Q: Miles Dixon of Peel Hunt asked for an update on what has happened since the August trading update, including whether Durham being online and new program wins have begun to reverse the timing issues previously flagged. A: CFO Lucinda Crabtree said yes Durham is online, the service offering is in place, and pipeline is converting into contracted orders that will convert to revenue, with momentum expected to build. Chief Commercial Officer Sebastien Ribault described the Durham delay as a technical issue that has been fixed, with key people put in place and team dynamics restored, characterizing it as a normal high and low of integrating a new facility into the network.

Q: Analysts probed the commercial momentum metrics, including the jump in contracted orders from GBP97 million at the half year to GBP127 million by end of August and revenue backlog growth from GBP193 million to GBP299 million. A: CEO Frank Mathias said the movement reflects successful conversion of opportunities into signed client orders rather than any reduction in underlying demand, strengthening visibility of future revenues. He noted 17 new clients signed in H1 2026 more than 30% of the total signed in all of 2025 rising to 21 by the time of the call, and 22 with another client signed overnight, with the commercial pipeline at $713 million at the half year versus $659 million at end of August.

Q: Analysts asked about the impact of reported fatalities in some CAR T clinical trials for autoimmune diseases on OXB's programs and outlook. A: CEO Frank Mathias expressed that the events are devastating for affected patients and families, but made clear OXB has not seen any related issues in the few programs it is involved in, and as a result the company's outlook remains unaffected.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .